- Home
- OFRM vs ETON Comparison
OFRM vs ETON Comparison
Compare OFRM & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OFRM | ETON |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | 153 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 684.3M | 689.8M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | OFRM | ETON |
|---|---|---|
| Price | $15.85 | $29.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | $27.75 | ★ $39.33 |
| AVG Volume (30 Days) | 369.2K | ★ 371.2K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $79,950,000.00 |
| Revenue This Year | $29.42 | $40.90 |
| Revenue Next Year | $34.69 | $47.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 104.94 |
| 52 Week Low | $14.16 | $13.09 |
| 52 Week High | $27.00 | $32.31 |
Technical Indicators
Market Signals| Indicator | OFRM | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 51.89 | 64.45 |
| Support Level | $15.76 | $15.79 |
| Resistance Level | $17.06 | N/A |
| Average True Range (ATR) | 0.90 | 1.53 |
| MACD | 0.21 | 0.47 |
| Stochastic Oscillator | 66.24 | 70.34 |
Price Performance
Historical ComparisonAbout OFRM Once Upon a Farm PBC
Once Upon a Farm PBC is a provider of baby food products. The company provides childhood nutrition with real, organic, farm-fresh food-made with no added sugar, no preservatives, and nothing artificial. Its products are available at retail customers, including Target, Whole Foods, Kroger, Walmart, Publix, and Wegmans. Its key products include Smoothies, Yogurt, Milk Shakes, Oat Bars, etc.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.